期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺鳞状细胞癌分子特征及治疗对策研究现状 被引量：4

Molecular alterations and therapeutic strategies in squamous-cell carcinoma of the lung
原文传递
导出
摘要 目的:总结肺鳞状细胞癌分子特征改变的研究现状及相关临床试验结果,探讨肺鳞癌的个体化治疗策略。方法:应用PubMed、CBM、CNKI和Medline数据库检索系统,以"肺鳞状细胞癌、突变、过表达、扩增和临床试验"及相关因子名称为关键词,检索2000-01-2012-08的相关文献。纳入标准:1)肺鳞癌细胞存在的分子生物学改变;2)相关靶向治疗药物的临床试验进展。符合分析的文献27篇。结果:肺鳞癌细胞的一组分子特征改变在肺鳞癌发生发展过程中发挥了重要作用,根据治疗靶点的不同,可分为膜受体、信号通路分子和转录因子3类,其中膜受体包括FGFR1、IGF-1R、EGFRvⅢ、PDGFRA、DDR2和MET;信号通路分子包括PIK3CA、AKT1、PTEN和B-RAF;转录因子包括SOX2和Nrf2;基于这些靶点的靶向治疗药物陆续进入临床试验阶段并取得了一定的进展。结论:在肺鳞癌的诊治中,分子特征的检测应受到更多的重视,分子特征改变的研究不仅有助于明确肿瘤的生物学特性,而且可以为患者选择更加合理的、个体化的治疗方案。 OBJECTIVE：To summarize the research progress of molecular alterations and new therapeutic strategies in squamous-cell carcinoma of the lung. METHODS： The papers from January 2000 to October 2012 were searched with ＂squamous-cell carcinoma of the tung＂ ,＂somatic mutation＂ ,＂amplification＂ ,＂overexpression＂ ,＂clinical trial＂ and name of the cytokines as key words in PubMed, CBM,CNKI, Medline database, and 27 papers were selected according to the fol- lowing standards： 1） molecular alterations in squamous-cell carcinoma of the lung. 2）clinical trials of drugs targeting these molecular defects. RESULTS： A group of molecular alterations played an important role in development and progression of squamous cell carcinoma of the lung. We classify these molecular alterations as membrane receptor alterations, signaling pathway alterations and transcription factor alterations according to their therapeutic targets. Numerous prospective clini- cal trials targeting these molecular defects have been carried out and showed promising outcomes. CONCLUSION： The recognition of molecular characteristics is helpful to identify tumors with different biological behavior, and molecular sub- types can potentially be used to select personalized therapeutic stategy.
作者 王栋 刘相燕 宋永明 王洲
机构地区 山东大学附属省立医院胸外科
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第16期1287-1290,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 肺鳞状细胞癌 分子特征改变 治疗策略 综述文献 squamous-cell carcinoma of the lung molecular alteration therapeutic strategy review literature
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Weiss J,Sos ML,Seidel D,et al. Frequent and focal FGFR1 am- plification associates with therapeutically tractable FGFR] de- pendency in squamous cell lung cancer [J]. Sei Transl Med, 2010,2(62) : 62ra93.
  • 2Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, et al. Defi- nition of a fluorescence in-situ hybridization score identifies high- and lowqevel FGFR1 amplification types in squamous cell lung cancer[J]. Mod Pathol,2012,25(ll) :1473-1480.
  • 3Reck M, Kaiser R, Eschbach C, et al. A phase H double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed ad- vanced non-small-cell lung caneer[J] Ann Oneol, 2011,22 (6) : 1374 1381.
  • 4Nakagawa M, Uramoto H,Oka S, et al. Clinical significance of IGF1R expression in non-small-cell lung eancer[J]. Clin LungCancer,2012,13(2) : 136-142.
  • 5Ludovini V, Bellezza G, Pistola L, et al. High coexpression of both insulin-like growth factor receptor-I (IGFR-1) and epider- mal growth factor receptor (EGFR) is associated with shorter disease free survival in resected non-small-cell lung cancer pa- tients[J]. Ann Oncol, 2009,20 (5) : 842-849.
  • 6Karp DD,Paz-Ares LG,Novello S,et al. Phase ]1 study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and earboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer{J]. J Clin Oncol,2009,27(15) :2516-2522.
  • 7Ji H,Zhao X,Yuza Y,et al. Epidermal growth factor receptor variant llI mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors[J]. Proc Natl Acad Sci U S A, 2006, 103(20) :7817-7822.
  • 8Uribe P,Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin,molecular bases for EG- FR-targeted therapy. [J]. Pathol Res Pract, 2011,207 (6) : 337- 342.
  • 9Ramos AH, Dutt A, Mermel C, et al. Amplification of chromo- somal segment 4q12 in non-small cell lung cancer{J]. Cancer Bi- ol Ther,2009,8(21) :2042-2050.
  • 10Shah GD,Loizos N, Youssoufian H, et al. Rationale for the de- velopment of IMC-3G3, a fully human immunogiobulin G sub- class 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha{J]. Cancer, 2010, 116 (4 Suppl):1018 1026.

二级参考文献15

  • 1郁宝铭.进一步提高直肠癌疗效的策略[J].中华肿瘤防治杂志,2007,14(2):81-84. 被引量：10
  • 2Normanno N, Bianco C, De Luca A, et al. Target-based agents anainst ErbB receptors and their ligands: a novel approach to cancer treamtent[J]. Endocr Relat Cancer, 2003, 10(1): 1- 21.
  • 3Sambrook J, David R. Molecular Cloning (Third Edition) [M]. America:CSHL Press, 2000: 1235-1262.
  • 4Nyati M K, Morgan M A, Feng F Y, et al. Intergration of EGFR inhibitors with radiochemotherapy[J]. Nat Ca Rev, 2006, 6 (4) :876-885.
  • 5Ingo K, Tim F, Paul S, et al. PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors[J]. Clin Cancer Res, 2007, 13(2) :378-382.
  • 6Endoh H, Yatabe Y, Kosaka T, et al. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients[J]. J Thorae Oncol, 2006, 1(7): 629 634.
  • 7Justin S, Issei T, Sandra M, et al. PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme[J]. JNCI, 2001, 93(16) : 1246-1256.
  • 8Ingo K, Maria Y, Igor V, et al. Molecular Determinants of the Response of Gliololastomas to EGFR Kinase Inhibitors[J]. N Engl J Med, 2006,354(8) : 2012- 2024.
  • 9Haas-Kogan D A, Prados M D, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib[J]. J Natl Cancer Inst, 2005,97(5):880-887.
  • 10She Q B, Solit Q, Reilly K E, et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells[J]. Cancer Cell, 2005,8(1) : 287-297.

共引文献2

同被引文献87

  • 1于宝华,周晓燕.PI3K/Akt/mTOR的信号传导通路在恶性肿瘤中的研究进展[J].中华病理学杂志,2005,34(10):674-676. 被引量：21
  • 2余宗阳,欧阳学农,杜建,季天海,李捷.非小细胞肺癌中胰岛素样生长因子-1受体的表达[J].福州总医院学报,2006,13(4):202-204. 被引量：1
  • 3Piperdi B, Merla A, Perez-Soler R. Targeting angiogenesis in squamous nonsmall cell lung cancer. Drugs, 2014, 74(4): 403-413.
  • 4Mitsudomi T, Morita S, Yatabe Y, ei al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).J Clin Oncol, 2012, 30 (Suppl). Abstr 7521.
  • 5Mok TS, Wu YL, Yu cj, et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.J Clin Oncol, 2012, 30(Supp!): Abstr 7520.
  • 6Mu XL, Li LY, Zhang XT, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with nonsmall cell lung cancer. Clin Cancer Res, 2005, 1l(12): 4289-4294.
  • 7Lai Y, Zhang Z, LiJ, et al. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. IntJ Mol Sci, 2013, 14(12): 24549-24559.
  • 8Hata A, Katakami N, Yoshioka H, et al. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?J Thorac Oncol, 2013, 8( 1): 89-95.
  • 9Shukuya T, Takahashi T, Kaira R, et al. Efficacy of gefitinib for nonadeancareinoma non-small cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci, zou, 102(5): 1032-1037.
  • 10Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res, 2008, 68( 17): 69l3-6921.

引证文献4

二级引证文献16

中华肿瘤防治杂志
2013年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部